Free Trial

LENSAR (LNSR) Stock Price, News & Analysis

LENSAR logo
$5.88 -0.13 (-2.08%)
As of 01:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About LENSAR Stock (NASDAQ:LNSR)

Advanced

Key Stats

Today's Range
$5.75
$6.00
50-Day Range
$5.09
$6.58
52-Week Range
$5.06
$13.74
Volume
14,809 shs
Average Volume
88,096 shs
Market Capitalization
$71.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

LENSAR Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

LNSR MarketRank™: 

LENSAR scored higher than 47% of companies evaluated by MarketBeat, and ranked 634th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LENSAR has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    LENSAR has a consensus price target of $10.00, representing about 70.2% upside from its current price of $5.88.

  • Amount of Analyst Coverage

    LENSAR has only been the subject of 3 research reports in the past 90 days.

  • Read more about LENSAR's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LENSAR is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LENSAR is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LENSAR has a P/B Ratio of 6.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LENSAR's valuation and earnings.
  • Percentage of Shares Shorted

    23.07% of the float of LENSAR has been sold short.
  • Short Interest Ratio / Days to Cover

    LENSAR has a short interest ratio ("days to cover") of 14.35, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENSAR has recently decreased by 2.71%, indicating that investor sentiment is improving.
  • Dividend Yield

    LENSAR does not currently pay a dividend.

  • Dividend Growth

    LENSAR does not have a long track record of dividend growth.

  • News Sentiment

    LENSAR has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for LENSAR this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for LNSR on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LENSAR insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    66.00% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LENSAR's insider trading history.
Receive LNSR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LNSR Stock News Headlines

Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
See More Headlines

LNSR Stock Analysis - Frequently Asked Questions

LENSAR's stock was trading at $11.63 at the beginning of the year. Since then, LNSR stock has decreased by 49.5% and is now trading at $5.8750.

LENSAR, Inc. (NASDAQ:LNSR) announced its quarterly earnings results on Friday, May, 8th. The company reported $1.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $1.38. The business earned $13.43 million during the quarter, compared to the consensus estimate of $13.40 million. LENSAR had a negative trailing twelve-month return on equity of 183.19% and a net margin of 50.94%.
Read the conference call transcript
.

LENSAR's top institutional shareholders include Groupe la Francaise (1.76%), Credit Industriel ET Commercial (1.19%), Evernest Financial Advisors LLC (0.55%) and Deltec Asset Management LLC (0.54%).
View institutional ownership trends
.

Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), Baidu (BIDU), Cidara Therapeutics (CDTX) and Carlyle Group (CG).

Company Calendar

Last Earnings
5/08/2026
Today
5/29/2026
Next Earnings (Estimated)
8/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LNSR
CIK
1320350
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$10.00
Potential Upside/Downside
+70.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.28 million
Net Margins
50.94%
Pretax Margin
50.94%
Return on Equity
-183.19%
Return on Assets
42.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.38
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$58.44 million
Price / Sales
1.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.89 per share
Price / Book
6.60

Miscellaneous

Outstanding Shares
12,100,000
Free Float
4,115,000
Market Cap
$71.09 million
Optionable
Optionable
Beta
0.84

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:LNSR) was last updated on 5/29/2026 by MarketBeat.com Staff.
From Our Partners